Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib. - Wikidata - awgldk - TriplyDB

Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.

Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.

http://www.wikidata.org/entity/Q39348852

about

Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions Anti-angiogenic agents in metastatic colorectal cancer Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy.Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts.Emerging tyrosine kinase inhibitors for the treatment of renal cancer.Novel anti-angiogenic therapeutic strategies in colorectal cancer.Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas.Famitinib enhances nasopharyngeal cancer cell radiosensitivity by attenuating radiation-induced phosphorylation of platelet-derived growth factor receptor and c-kit and inhibiting microvessel formation.Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.Emerging drugs for the treatment of gastrointestinal stromal tumour.New targets and therapies for gastrointestinal stromal tumors.Latest advances in adult gastrointestinal stromal tumors.Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer.

P2860

Q26799387-DF8EA8F9-F4E4-44FC-9DFA-FFF8594A38B7 Q26801911-CB75F219-60AB-4801-80C4-5EFA43BBAEFF Q36720067-006020D8-ED49-42C7-8F43-6B89A0C1A776 Q37204806-AF9EA194-FD5E-4564-BD24-F88C065A77AE Q38485779-298202D8-D87E-40F5-BEAC-5BA44670E4D9 Q38759141-C3CE7140-6FAF-441B-A60F-3570842C4C09 Q38794338-214A027E-9CFD-4B95-8D3C-D5087CAA886A Q38838220-D3BAD3D3-5186-4145-8FC4-BAABB091FCB8 Q38864184-B0A048FE-7FB5-4EDC-85FC-61BE6D333C87 Q38925022-8EDE9843-CC98-40DD-A099-CC9E03799CCC Q38979882-9B06E6A5-DA72-4B8C-BF0A-46185CA1F2AC Q47104695-C04FCE73-588A-42D5-9A1F-5338D1CB63EB Q47355982-11B0283A-6332-41FB-A628-A28043D91E86 Q47432725-8CA969EF-F040-44B9-B037-B0B364923046 Q47912361-4F70485F-367F-402F-96CD-2603FCD9FFC5 Q54344097-D13A324F-0308-4112-B237-C30F689D07CA

P2860

Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.

http://www.wikidata.org/entity/Q39348852

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.

@en

Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.

@nl

type

label

Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.

@en

Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.

@nl

prefLabel

Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.

@en

Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.

@nl

P1433

Q39348852-A21E6A6C-936A-4CC5-92C0-F3DDB7F005EA

P1476

Q39348852-A62A75FC-EE05-4FD6-8576-82CF242ACE65

P2093

Q39348852-3D89990B-EAD7-498E-ABD6-E046D8BE29CD

Q39348852-48A19715-1A50-4EEB-8148-3DC3F305A80F

Q39348852-6CCAD7BD-CA02-4688-ADD2-163A8A63283D

Q39348852-74BC259D-6077-4D3A-A123-D259D8DEB556

Q39348852-BBE419BB-D77F-4A07-919A-E586DCF81219

Q39348852-C4F045C6-771C-437E-A566-21BFF054D123

Q39348852-C6473BCF-761E-4037-AFAF-76CC7E1FFC17

Q39348852-D306E328-0E22-497E-9560-08880F738E2D

Q39348852-F5AAFCA4-9F95-4F88-A978-94EC7220977B

P2860

Q39348852-028F411A-6152-4018-9F74-7918B0FCF709

Q39348852-12EE38DE-4889-426B-BA60-725459E09316

Q39348852-1365D5ED-8F92-4BD7-9856-105381819589

Q39348852-16203447-9515-41E9-B3D6-F6B275F43FC6

Q39348852-34BD128C-08B7-46D7-BD69-41CB255E8BA2

Q39348852-36830C1F-8DCA-48AD-AC4F-DFAEC814E562

Q39348852-482F355D-AC04-4F8F-ABCB-4786C553BC63

Q39348852-5BAA4D9D-4F6B-4461-9D4A-AAC33A24DF6F

Q39348852-5D67282D-19A0-4F38-954F-97BF03768CE1

Q39348852-64490E62-64B0-41E6-91EC-DA2BF949CE33

P2888

Q39348852-828505D0-8E2D-47FE-A7CE-AD014B53CB8B

P304

Q39348852-B7251A34-6780-4418-915F-A043D68FA024

P31

Q39348852-2D00B22C-E118-4B07-A911-7006B92DC76E

P356

Q39348852-FA349295-3B79-4E32-853A-7CFF8826BAE1

P433

Q39348852-B4092FB7-2351-4670-B63C-AFCC2DC5E226

P478

Q39348852-6807D233-EA74-44C0-9A4A-644B2B3C44F1

P577

Q39348852-26C19E6A-2742-46EC-B117-CBA6B94D74F8

P5875

Q39348852-6EE0EE0A-B77B-4D57-8376-19D8C19D9DEA

P698

Q39348852-41E63357-AAC0-40B3-BC87-E1F7F380F187

P356

S00280-013-2282-Y

P1433

Cancer Chemotherapy and Pharmacology

P1476

Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.

@en

P2093

Aiping Zhou

http://www.w3.org/2001/XMLSchema#string

Chunxiao Chang

http://www.w3.org/2001/XMLSchema#string

Dafang Zhong

http://www.w3.org/2001/XMLSchema#string

Donghua Lou

http://www.w3.org/2001/XMLSchema#string

Haoyuan Jiang

http://www.w3.org/2001/XMLSchema#string

Jinwan Wang

http://www.w3.org/2001/XMLSchema#string

Qiong Qin

http://www.w3.org/2001/XMLSchema#string

Wen Zhang

http://www.w3.org/2001/XMLSchema#string

Xiaoyan Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Sorafenib in advanced hepatocellular carcinoma

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea

The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.

P2888

s00280-013-2282-y

P304

1043-1053

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-013-2282-Y

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256665886

http://www.w3.org/2001/XMLSchema#string

P698

24043137

http://www.w3.org/2001/XMLSchema#string